Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2. Issue 2 (22nd December 2019) - Barley, Kevin; Sanchez, Larysa; Cho, Hearn J.; Parekh, Samir; Madduri, Deepu; Richter, Joshua; Isola, Luis; Goldstein, Talia; Dhadwal, Amishi; Zarychta, Katarzyna; Sanchez, Gillian Morgan; Catamero, Donna; et al.